Navigation Links
A diagnosis of triple-negative breast cancer doesn't always mean cancer spread
Date:4/11/2008

Triple-negative breast cancers are a heterogeneous group and may not always be associated with lymph node spread, a new study shows.

The study of 145 triple negative breast cancers (i.e, cancer which is estrogen receptor-negative, progesterone receptor-negative and HER2-negative) in 128 women found that about 23% were moderate or low-grade lesions, said Cecilia Mercado, MD, of New York University School of Medicine, and an author of the study.

Triple negative breast cancer is found in about 15% of breast cancer patients and the patients are usually younger.

The study found that 11 of the 145 cancers had a low histologic grade. Only one of these patients had evidence that their cancer had spread into their lymph nodes. Twenty-three cancers were moderate grade lesions; only five of these 23 had spread into the lymph nodes. That compares to 37 of 111 cancers with a high histologic grade which had lymph node metastases, Dr. Mercado said.

Our preliminary results show that triple negative breast cancers are a heterogeneous group. Although many are high grade lesions, some are moderate or low grade demonstrating a lower rate of lymph node metastasis, Dr. Mercado said.


'/>"/>

Contact: Necoya Tyson
necoya@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Page: 1

Related medicine news :

1. New pan-European collaboration launched into the diagnosis and control of coeliac disease
2. Study supports theory that rise in autism is related to changes in diagnosis
3. Schizophrenia: Diagnosis Is Not Destiny - Conference
4. Hospital Clinic awarded by CEREBRA Foundation for its excellence in early diagnosis of brain damage
5. CMS Approves Home Sleep Testing for Diagnosis of OSA; AASM Experts Available for Comment
6. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
7. New techniques improve imaging quality, not diagnosis of Barretts esophagus
8. New TB test means quicker and easier diagnosis for patients
9. Patrick Swayzes Diagnosis With Pancreatic Cancer: a Statement From the Pancreatic Cancer Action Network
10. PETs targeted imaging may lead to earlier diagnosis of dementia and Alzheimers disease
11. Comprehensive diagnosis of heart disease with a single CT scan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... Albuquerque, NM (PRWEB) , ... December 06, 2016 ... ... awarded JumpStart Autism Center with an Award of Distinction, recognizing the organization as ... needs providers that excel in the areas of clinical quality, staff satisfaction and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, ... offering HIAC particle counting and sizing services for USP 788 and 789 particulate ... new service as a response to the needs of pharmaceutical and medical device ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... November 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind ... design. Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:12/6/2016)... Georgia (PRWEB) , ... December 06, 2016 , ... ... consecutive year to "Training" magazine’s 2017 Training Top 125 for their industry leading ... This prestigious, annual award recognizes USA as among the global elite in employer-sponsored ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016 /PRNewswire/ - InMed Pharmaceuticals, ... today on its R&D program in the use ... pulmonary disease (COPD). In June, 2015 InMed initiated ... to identify the targets and potential active compounds ... COPD. Subsequently, with in vitro assays using human ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
(Date:12/5/2016)... 5, 2016 Sangamo BioSciences, Inc. (Nasdaq: ... presentation of preclinical and manufacturing data that support SB-525, its ... Annual Meeting of the American Society of Hematology (ASH) ... from December 3-6, 2016. "We have developed an ... we believe is highly competitive, and we remain on track ...
Breaking Medicine Technology: